Clinical trial · Interventional
Target-specific immunoPET Imaging of Digestive System Carcinoma
Development and Clinical Translation of immunoPET Imaging Probes for Digestive System Carcinoma
NCT06715839CI-TRIAL-00099899recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to establish and optimize the target-specific PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in digestive system malignant tumors will be evaluated.
Conditions
Conditions (15)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Appendix Cancer | Malignant Appendix Neoplasm | ALIAS | 0.90 |
| Bile Duct Carcinoma | Cholangiocarcinoma | ALIAS | 0.90 |
| Colon Cancer | Malignant Colon Neoplasm | CURATED_EXACT | 0.92 |
| Digestive Cancer | — | UNRESOLVED | — |
| Digestive System Cancer | Malignant Digestive System Neoplasm | ALIAS | 0.90 |
| Digestive System Carcinoma | Digestive System Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Digestive System Neoplasm | Digestive System Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Esophagus Cancer | — | UNRESOLVED | — |
| Gallbladder Carcinoma | Gallbladder Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (10)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [18F]F-RESCA-G5 | Drug | — | UNRESOLVED |
| [18F]F-RESCA-RB14 | Drug | — | UNRESOLVED |
| [18F]F-RESCA-RND20 | Drug | — | UNRESOLVED |
| [18F]F-RESCA-T4 | Drug | — | UNRESOLVED |
| [18F]F-RESCA-WWH347 | Drug | — | UNRESOLVED |
| [68Ga]Ga-DOTA-H2D3 | Drug | — | UNRESOLVED |
| [68Ga]Ga-NOTA-G5 | Drug | — | UNRESOLVED |
| [68Ga]Ga-NOTA-RND20 | Drug | — | UNRESOLVED |
| [68Ga]Ga-NOTA-T4 | Drug | — |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- ImmunoPET imaging in patients with digestive system carcinoma
- description
- Enrolled patients will undergo a targeted-specific immunoPET/CT scanning.
- interventionNames
- Drug: [68Ga]Ga-DOTA-H2D3
- Drug: [18F]F-RESCA-RB14
- Drug: [68Ga]Ga-NOTA-T4
- Drug: [18F]F-RESCA-T4
- Drug: [68Ga]Ga-NOTA-G5
- Drug: [18F]F-RESCA-G5
- Drug: [68Ga]Ga-NOTA-WWH347
- Drug: [18F]F-RESCA-WWH347
- Drug: [68Ga]Ga-NOTA-RND20
- Drug: [18F]F-RESCA-RND20
Primary outcomes (5)
- measure
- Biodistribution
- timeFrame
- 1 day from injection of the tracers
- description
- Measurement of the overall biodistribution of above tracers in normal tissues and organs.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Aged 18-75 years old and of either sex； 2. Histologically confirmed diagnosis of digestive system carcinoma or suspected digestive system carcinoma by diagnostic imaging; 3. Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol. Exclusion Criteria: 1. Pregnancy； 2. Severe hepatic and renal insufficiency; 3. History of serious surgery in the last month; 4. Allergic to antibody or single-domain antibody radiopharmaceuticals.
References
Publications (0)
Data not yet available
No reference posted for this study.